Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.38 |
| ▸ | CNR1 | P21554 | 6/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7732349 | 0.88 | CA2 (0.33) | CA2CA1ALDH1A1POLBTYR | |
| SCHEMBL7528155 | 0.86 | ALDH1A1 (0.33) | CA2CA1ALDH1A1POLBTYR | |
| SCHEMBL6306672 | 0.86 | ALDH1A1 (0.33) | CA2CA1ALDH1A1POLBTYR | |
| SCHEMBL7533231 | 0.86 | ALDH1A1 (0.33) | CA2CA1ALDH1A1POLBTYR | |
| SCHEMBL6308900 | 0.77 | CA2 (0.40) | MEN1KMT2ACA2CA1ALDH1A1 | |
| SCHEMBL7522979 | 0.74 | CA2 (0.33) | CA2CA1ALDH1A1POLBTYR | |
| SCHEMBL7524824 | 0.74 | CA2 (0.33) | MEN1KMT2ACA2CA1ALDH1A1 | |
| Dimethylamine SCHEMBL6307740 | 0.74 | CA2 (0.37) | MEN1KMT2ACA2CA1ALDH1A1 | |
| SCHEMBL6306885 | 0.73 | ALDH1A1 (0.33) | MEN1KMT2ACA2CA1ALDH1A1 | |
| SCHEMBL7523511 | 0.73 | CA2 (0.33) | CA2CA1ALDH1A1POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159476-A1 | Pharmaceutical composition for preventing or treating respiratory disease | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-07-21 | — | — | US | disclosed |
| US-6133279-A | A 2,6-DI-T-BUTYLPHENOL DERIVATIVE FOR RENAL DISEASES, E.G., CHRONIC RENAL FAILURE, DIABETIC NEPHROPATHY GLOMERULAR NEPHRITIS, IMMUNOCOMPLEX NEPHRITIS AND ACUTE RENAL FAILURE; CYTOPROTECTIVE AGENT THAT INHIBITS THE LIPID PEROXIDATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0950405-A1 | REMEDIES FOR RENAL DISEASES AND ORGAN-PRESERVING AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159476-A1 | Pharmaceutical composition for preventing or treating respiratory disease | CFTR, CMA1, SLC5A1 | CNR2 2414/4885CNR1 1582/4885IDH1 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.